Exclusive: US FDA to request Sarepta to stop all shipments of gene therapy Elevidys, source says

Sarepta Therapeutics (SRPT.O) shares plunged nearly 35% after Reuters reported the U.S. FDA will request a voluntary halt to all shipments of its gene therapy, Elevidys. This action follows the deaths of two teenage boys treated with Elevidys for Duchenne muscular dystrophy, prompting FDA Commissioner remarks about reviewing the therapy's market status. Investor concerns are further amplified by a recently disclosed death in an early-stage trial for Sarepta's experimental LGMD gene therapy, SRP-9004, due to acute liver failure.

Analysis

Sarepta Therapeutics is facing a severe operational and regulatory challenge, as evidenced by a report that the U.S. FDA will request a complete halt to all shipments of its key gene therapy, Elevidys. This development, which prompted a precipitous stock decline of nearly 35%, marks a significant escalation from a prior, more limited shipment pause. The FDA's action is a direct response to two patient deaths in its Duchenne muscular dystrophy program. Compounding these concerns is the separate disclosure of a fatality from acute liver failure in an early-stage trial for another of the company's gene therapies, SRP-9004, raising broader questions about the safety profile of its underlying technology platform. The situation is critically intensified by the FDA Commissioner's public statement about "taking a hard look" at whether Elevidys should remain on the market, introducing a material risk of a full product withdrawal and creating a significant overhang on the company's primary revenue source.

Key Decisions for Investors

• Investors holding SRPT should urgently reassess their position in light of the tangible risk of a full market withdrawal for Elevidys, which could further erode shareholder value.
• Extreme caution is warranted for those considering entering a position, as the current news presents substantial downside risk with no clear path to resolution until formal regulatory clarity is provided by the FDA.
• Monitor all forthcoming communications from both the FDA and Sarepta's management, as the official terms of the shipment halt and the company's strategic response will be critical in determining the therapy's future viability.